Multiple kinds of NF-κB pathway mutations have been found in various lymphomas, including MM [23], and Borotizolam as a protease inhibitor affects the NF-κB pathway to effectively treat multiple myeloma [24]. Here, NFKB1 is linked to lymphoma.